Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 7/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827603 | 0.87 | SSTR1 (0.47) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL27054862 | 0.86 | SELP (0.37) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL27055270 | 0.85 | SELP (0.38) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL26452998 | 0.82 | SELP (0.37) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL30829386 | 0.81 | SELP (0.43) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL27054888 | 0.80 | CETP (0.53) | SELPCETP | |
| SCHEMBL27055012 | 0.80 | SELP (0.42) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13377703 | 0.78 | SSTR1 (0.44) | SELPSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16772350 | 0.77 | SELP (0.37) | SELP | |
| SCHEMBL27054999 | 0.77 | SELP (0.37) | SELPSSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | SELP 344/4885SSTR1 2769/4885SSTR2 1743/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | SELP 237/4885SSTR1 2127/4885SSTR2 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.